Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Botox Reimbursement Training Is Driving Factor In Allergan Settlement With DOJ

This article was originally published in The Pink Sheet Daily

Executive Summary

Allergen will pay $600 million for promoting the drug for headache and spasticity; government says company taught physicians how to bill for off-label uses.

You may also be interested in...



FDA First Amendment Litigation: Will Amarin Case Break The Log Jam?

Courts have issued mixed rulings in cases challenging FDA restrictions on drug promotion, but with oral arguments set for July 7, Amarin’s suit could provide a definitive answer on what companies can tell physicians.

Declaring Victory: How FDA Releases REMS

There is a new category of FDA action letter: a REMS release. Dozens of sponsors of “MedGuide-only” REMS received them after an FDA policy change. But now, FDA is issuing them regularly to sponsors whose communication plans have met their goals – or at least run their course.

FDA Hit With Slew Of Suits As Firms Fight For Market Advantage

At least nine complaints have been filed against the agency since March, most involving market exclusivity claims; lawyers expect innovators will be pursuing more cases as patents expire and biosimilars emerge.

Related Content

Topics

UsernamePublicRestriction

Register

PS071147

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel